Giredestrant vs Imlunestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Giredestrant

Marketed by Roche

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04546009 · Phase 3 · active, not recruiting

This was a large (n=992), randomized, double-blind, active-controlled phase 3 trial using progression-free survival, a hard clinical endpoint, as its primary measure -- a strong design overall. However, the reported result showed only a numerical trend favoring giredestrant that did not reach statistical significance, so the trial does not provide confirmed evidence of benefit despite its rigorous design.

Next expected readout: July 2027 · NCT03332797 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)): persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. (missed)

Result source: NCT04546009

Imlunestrant · Inluriyo

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04975308 · Phase 3 · active, not recruiting

EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.

Next expected readout: October 2028 · NCT07905001 (registry estimate)

Reported efficacy

Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)

Result source: NCT04975308

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointGiredestrantImlunestrant
PFS, median—Trial running · NCT060657485.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results
OS, median—Trial running · NCT06065748—Trial running · NCT04975308
ORR—Trial running · NCT0606574810.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
Clinical benefit rate—Trial running · NCT0606574846.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results

PFS, median

Giredestrant
—Trial running · NCT06065748
Imlunestrant
5.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results

OS, median

Giredestrant
—Trial running · NCT06065748
Imlunestrant
—Trial running · NCT04975308

ORR

Giredestrant
—Trial running · NCT06065748
Imlunestrant
10.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results

Clinical benefit rate

Giredestrant
—Trial running · NCT06065748
Imlunestrant
46.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Giredestrant: 3 of 4 rows · Imlunestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGiredestrantImlunestrant
Dropout rate
8.7%a
NCT05659563 · Phase 2 · registry result, not featured evidence
25.7%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
45.1%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
—a
NCT05659563 · Phase 2 · registry result, not featured evidence
3%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5.6%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
0%a
NCT05659563 · Phase 2 · registry result, not featured evidence
14.1%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.2%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
a
arthralgia 9.5%
hot flush 9.5%
fatigue 7.1%
NCT05659563 · Phase 2 · registry result, not featured evidence
diarrhoea 21.7%
nausea 18%
arthralgia 15.3%
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 86.5%
nausea 50%
anaemia 43.8%
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Giredestrant

Ki67 -14.5% (n=40) vs -10% (n=44) Tamoxifen @ 2.14wk
absolute change · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence
Complete Cell Cycle Arrest 17.5% (n=40) vs 4.5% (n=44) Tamoxifen @ 2.14wk
absolute value · percentage points
NCT05659563 · Phase 2 · registry result, not featured evidence

Imlunestrant

PFS 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS 9.36 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.52 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 21.1% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
9.4% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.07 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 62.9% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
44.1% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Giredestrant's landscape · Imlunestrant's landscape